<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Eur. J. Clin. Pharmacol</journal-id><journal-title-group><journal-title>European Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0031-6970</issn><issn pub-type="epub">1432-1041</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29198060</article-id><article-id pub-id-type="pmc">5808057</article-id><article-id pub-id-type="publisher-id">2392</article-id><article-id pub-id-type="doi">10.1007/s00228-017-2392-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacogenetics</subject></subj-group></article-categories><title-group><article-title>No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vizeli</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Meyer zu Schwabedissen</surname><given-names>Henriette E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1765-9659</contrib-id><name><surname>Liechti</surname><given-names>Matthias E.</given-names></name><address><phone>+41 61 328 68 68</phone><email>matthias.liechti@usb.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, Department of Clinical Research, University Hospital Basel, University of Basel, Schanzenstrasse 55, 4056 Basel, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0642</institution-id><institution-id institution-id-type="GRID">grid.6612.3</institution-id><institution>Biopharmacy, Department of Pharmaceutical Sciences, </institution><institution>University of Basel, </institution></institution-wrap>Basel, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>74</volume><issue>3</issue><fpage>275</fpage><lpage>283</lpage><history><date date-type="received"><day>21</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Methylenedioxymethamphetamine (MDMA, ecstasy) is used recreationally and frequently leads to sympathomimetic toxicity. MDMA produces cardiovascular and subjective stimulant effects that were shown to partially depend on the norepinephrine transporter (NET)-mediated release of norepinephrine and stimulation of &#x003b1;<sub>1</sub>-adrenergic receptors. Genetic variants, such as single-nucleotide polymorphisms (SNPs), of the NET gene (<italic>SLC6A2</italic>) may explain interindividual differences in the acute stimulant-type responses to MDMA in humans.</p></sec><sec><title>Methods</title><p id="Par2">We characterized the effects of common genetic variants of the <italic>SLC6A2</italic> gene (rs168924, rs47958, rs1861647, rs2242446, and rs36029) on cardiovascular and subjective stimulation after MDMA administration in 124 healthy subjects in a pooled analysis of eight double-blind, placebo-controlled studies.</p></sec><sec><title>Results</title><p id="Par3">Carriers of the GG genotype of the <italic>SLC6A2</italic> rs1861647 SNP presented higher elevations of heart rate and rate-pressure product after MDMA than subjects with one or no G alleles. Subjects with a C allele in the <italic>SLC6A2</italic> rs2242446 SNP presented higher elevations of the heart rate after MDMA administration compared with the TT genotype. Subjects with the AA genotype of the <italic>SLC6A2</italic> rs36029 SNP presented higher elevations of mean arterial pressure and rate pressure product after MDMA administration than carriers of the G allele. The <italic>SLC6A2</italic> rs168924 and rs47958 SNPs did not alter the response to MDMA.</p></sec><sec><title>Conclusions</title><p id="Par4">Genetic polymorphisms of the SLC6A2 gene weakly moderated the acute cardiovascular response to MDMA in controlled studies and may play a minor role in adverse cardiovascular events when MDMA is used recreationally.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s00228-017-2392-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>MDMA</kwd><kwd>Norepinephrine transporter</kwd><kwd>SLC6A2</kwd><kwd>Pharmacogenetics</kwd><kwd>Cardiostimulation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur F&#x000f6;rderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>320030_149493</award-id><award-id>320030_170249</award-id><principal-award-recipient><name><surname>Liechti</surname><given-names>Matthias E.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is used recreationally for its ability to enhance empathic feelings and sociability [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. MDMA has also been investigated as a treatment for posttraumatic stress disorder [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, MDMA produces adverse effects, including cardio- and psychostimulant effects to varying degrees [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. The sympathomimetic effects of MDMA vary across subjects, and high blood pressure responses were observed in a few subjects [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The response to MDMA varies between subjects, and genetic variations may explain some of this interindividual variation [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. For example, genetic variations of the enzymes that are involved in MDMA metabolism (mainly CYP2D6) have been shown to affect plasma levels of MDMA and its metabolites [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] and moderate the pharmacokinetics and partially the pharmacodynamics of MDMA. However, genetic variants of the pharmacological targets of MDMA [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>] may also moderate its pharmacodynamic effects, but such effects have not yet been studied.</p><p id="Par6">MDMA interacts with presynaptic monoamine transporters and mainly causes the transporter-mediated efflux of serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE; [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]). The transporter-mediated efflux of NE has been suggested to critically contribute to the cardio- and psychostimulant effects of MDMA [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. The solute carrier family 6 (neurotransmitter transporter, NE transporter [NET]), member 2 (<italic>SLC6A2</italic>) is a crucial player in the noradrenergic system and involved in the mechanism of action of MDMA in humans. Inhibition of the NET significantly attenuated the sympathomimetic stimulant-like effects of MDMA and other stimulant-type substances [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In a controlled study in healthy subjects, the NET inhibitor reboxetine reduced the MDMA-induced elevations of blood pressure and heart rate and subjective stimulation and increased the pupil diameter at rest and after light [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], indicating a role for the NET in mediating the MDMA response [<xref ref-type="bibr" rid="CR22">22</xref>]. Similarly, pretreatment with the NET inhibitor atomoxetine attenuated <sc>d</sc>-amphetamine-induced elevations of blood pressure and self-reported ratings of feeling &#x0201c;stimulated&#x0201d; [<xref ref-type="bibr" rid="CR20">20</xref>]. Another study in humans showed a similar reduction of cardiostimulant responses to cocaine after treatment with the NET inhibitor atomoxetine [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par7">Several genetic variations of the <italic>SLC6A2</italic> gene that are caused by single-nucleotide polymorphisms (SNPs) are associated with different functional phenotypes. However, the roles of these genotypes in the effects MDMA have not yet been investigated. Therefore, we focused on validated, polymorphic (minor allele frequency in Caucasians &#x0003e;&#x02009;0.1), and potentially functionally relevant variants of <italic>SLC6A2</italic>. Specifically, the G allele of the <italic>SLC6A2</italic> rs168924 SNP was associated with hypertension in Japanese patients [<xref ref-type="bibr" rid="CR24">24</xref>] but lower blood pressure in Caucasians [<xref ref-type="bibr" rid="CR25">25</xref>]. Subjects with the AA genotype of the <italic>SLC6A2</italic> rs1861647 SNP or CC genotype of the <italic>SLC6A2</italic> rs47958 SNP had higher subjective elation scores in response to <sc>d</sc>-amphetamine compared with carriers of the G allele [<xref ref-type="bibr" rid="CR26">26</xref>] or A allele [<xref ref-type="bibr" rid="CR27">27</xref>], respectively. The <italic>SLC6A2</italic> rs2242446 SNP was shown to influence blood pressure during exercise [<xref ref-type="bibr" rid="CR28">28</xref>]. Additionally, an association was found between the rs2242446 SNP and recurrent depression [<xref ref-type="bibr" rid="CR29">29</xref>] and antidepressant response to the 5-HT/NE transporter inhibitor milnacipran [<xref ref-type="bibr" rid="CR30">30</xref>]. Finally, the <italic>SLC6A2</italic> rs36029 SNP was shown to be significantly associated with alcohol dependence [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par8">The present study investigated the impact of genotypes within the noradrenergic system on the effects of MDMA. We evaluated whether the <italic>SLC6A2</italic> rs168924, rs47958, rs1861647, rs2242446, and rs36029 SNPs influence the cardiovascular and subjective stimulant effects of MDMA. MDMA-induced peak increases in the rate-pressure product (RPP) and subjective ratings of stimulation were considered the two primary endpoints. Plasma concentrations of MDMA and NE were determined to exclude possible confounding effects on the influence of genotype.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par9">This was a pooled analysis of eight Phase I double-blind, placebo-controlled, crossover studies in healthy subjects that used similar methods [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. These studies included a total of 136 healthy subjects. Seven studies included 16 subjects each, for a total of 112 subjects, who received 125&#x000a0;mg MDMA twice, once alone, and once after pretreatment with a medication [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. An additional study included 24 subjects who received 125&#x000a0;mg MDMA once alone, placebo, or other treatments [<xref ref-type="bibr" rid="CR36">36</xref>]. In the present analysis, only data from the MDMA-alone and placebo sessions were used. In all of the studies, the washout periods between single-dose administrations of MDMA were at least 7&#x000a0;days to exclude carry-over effects. The studies were all registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> (NCT00886886, NCT00990067, NCT01136278, NCT01270672, NCT01386177, NCT01465685, NCT01771874, and NCT01951508). All of the studies were approved by the local ethics committee and Swiss Agency for Therapeutic Products (Swissmedic). The studies were conducted in accordance with the Declaration of Helsinki. MDMA administration in healthy subjects was authorized by the Swiss Federal Office for Public Health (BAG), Bern, Switzerland. Informed consent was obtained from all of the participants who were included in the studies. All of the subjects were paid for their participation. Pharmacokinetic and safety data from these studies have been reported elsewhere [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. In all studies, test sessions took place in a quiet hospital research ward with no more than two research subjects present per session. The participants were comfortably lying in hospital beds and were mostly listening to music and did not engage in physical activities. MDMA was given without food in the fasting state in the morning at 8:00&#x02013;9:00 a.m.. A small standardized lunch was served at 12:00&#x02013;1:00 p.m.</p></sec><sec id="Sec4"><title>Subjects</title><p id="Par10">A total of 136 healthy European/Caucasian subjects, 18&#x02013;44&#x000a0;years old (mean&#x02009;&#x000b1;&#x02009;SD&#x02009;=&#x02009;24.8&#x02009;&#x000b1;&#x02009;4&#x000a0;years), were recruited from the University of Basel campus and participated in the study. One genotyping sample was missing, three participants did not give consent for genotyping, and eight subjects participated twice, and only the first participation was included, resulting in data from 124 subjects. The mean&#x02009;&#x000b1;&#x02009;SD body weight was 68&#x02009;&#x000b1;&#x02009;10&#x000a0;kg (range 46&#x02013;90&#x000a0;kg).</p><p id="Par11">The exclusion criteria included a history of psychiatric disorders, physical illness, a lifetime history of using illicit drugs more than five times (with the exception of past cannabis use), illicit drug use within the past 2&#x000a0;months, and illicit drug use during the study, determined by urine tests that were conducted before the test sessions as reported in detail elsewhere [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Thirty-eight subjects had prior illicit drug experiences (1&#x02013;5 times), of which 16 subjects had previously used MDMA (1&#x02013;2 times), 7 amphetamine or methamphetamine (1 time), 9 cocaine (1&#x02013;3 times), 6 lysergic acid diethylamide (1 time), and 11 psilocybin (1&#x02013;4 times).</p></sec><sec id="Sec5"><title>Study drug</title><p id="Par12">(&#x000b1;)MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was administered orally in a single dose of 125&#x000a0;mg, prepared as gelatin capsules (Bichsel Laboratories, Interlaken, Switzerland). Similar amounts of MDMA are found in ecstasy pills [<xref ref-type="bibr" rid="CR37">37</xref>] and have been used in clinical studies in patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The doses were not adjusted for body weight or sex. The dose per body weight (mean&#x02009;&#x000b1;&#x02009;SD) was 1.9&#x02009;&#x000b1;&#x02009;0.3&#x000a0;mg/kg (1.7&#x02009;&#x000b1;&#x02009;0.2&#x000a0;mg/kg for men and 2.1&#x02009;&#x000b1;&#x02009;0.3&#x000a0;mg/kg for women, range 1.4&#x02013;2.7&#x000a0;mg/kg).</p></sec><sec id="Sec6"><title>Cardiovascular effects</title><p id="Par13">Blood pressure and heart rate were assessed repeatedly before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6&#x000a0;h after MDMA or placebo administration. Systolic and diastolic blood pressure and heart rate were measured using an automatic oscillometric device (OMRON Healthcare Europe NA, Hoofddorp, Netherlands). The measurements were performed in duplicate at an interval of 1&#x000a0;min and after a resting time of at least 10&#x000a0;min. The averages were calculated for the analysis. Mean arterial pressure (MAP) was calculated as diastolic blood pressure&#x02009;+&#x02009;(systolic blood pressure&#x02009;&#x02212;&#x02009;diastolic blood pressure)&#x000a0;/&#x000a0;3. The RPP was calculated as <italic>systolic blood pressure</italic>&#x000a0;&#x000d7;&#x000a0;<italic>heart rate</italic> and was considered the primary cardiovascular measure that reflected overall cardiovascular stimulation.</p></sec><sec id="Sec7"><title>Subjective effects</title><p id="Par14">To assess subjective stimulation, a visual analog scale of &#x0201c;stimulated&#x0201d; was presented as a 100-mm horizontal line (0&#x02013;100%), marked from &#x0201c;not at all&#x0201d; on the left to &#x0201c;extremely&#x0201d; on the right [<xref ref-type="bibr" rid="CR1">1</xref>]. The scale was administered before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6&#x000a0;h after MDMA or placebo administration.</p></sec><sec id="Sec8"><title>Plasma concentrations of MDMA and norepinephrine</title><p id="Par15">Plasma levels of MDMA were determined before and 0.5, 1, 1.5, 2, 3, 4, and 6&#x000a0;h after drug administration [<xref ref-type="bibr" rid="CR34">34</xref>]. Plasma levels of NE were measured before and 2&#x000a0;h after drug administration as described previously [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec9"><title>Pupillometry</title><p id="Par16">Pupillometry was performed 1&#x000a0;h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, and 6&#x000a0;h after MDMA or placebo administration. Pupil function was measured under standardized dark-light conditions using a hand-held PRL-200 infrared pupillometer (NeurOptics, Irvine, CA) as reported previously in detail [<xref ref-type="bibr" rid="CR21">21</xref>]. Dark-adapted pupil diameter and minimal pupil diameter after a light stimulus were assessed.</p></sec><sec id="Sec10"><title>Genotyping</title><p id="Par17">Genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hombrechtikon, Switzerland) and automated QIAcube system. Genotyping was performed using commercial TaqMan SNP genotyping assays (LuBio Science, Lucerne, Switzerland) and the TaqMan Genotyping Master Mix. Fluorescence was detected using the ViiA7 real-time PCR system. We assayed the following <italic>SLC6A2</italic> SNPs: rs168924 (assay: C____581568_10), rs1861647 (assay: C___1232469_30), rs47958 (0.39, assay: C___3020083_10), rs2242446 (assay: C__26354911_10), rs36029 (C___1232432_10). We also assayed the following ADRA1A SNP: rs1048101 (assay: C___2696454_30). However, due to inconsistency with the Hardy-Weinberg equilibrium, we excluded the ADRA1A rs1048101 SNP from further analysis. The rs1861647 genotype could not be determined in one subject.</p></sec><sec id="Sec11"><title>Statistical analysis</title><p id="Par18">The statistical analyses were performed using Statistica 12 software (StatSoft, Tulsa, OK, USA). For repeatedly measured data, peak effects (E<sub>max</sub>) and areas under the effect-time curve (AUEC) from 0 to 6&#x000a0;h values were determined for MDMA and placebo. Differences in E<sub>max</sub> and AUEC values (MDMA-placebo) were then analyzed using one-way analysis of variance (ANOVA), with genotype as the between-group factor, followed by the Tukey post hoc test. The primary analysis did not control for the multiple comparisons, but a secondary analysis was conducted using Bonferroni correction for the five SNPs. To account for differences in plasma concentrations of MDMA that were caused by differences in body weight, dosing, or metabolizing enzymes [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], the area under the MDMA plasma concentration-time curve from 0 to 6&#x000a0;h (AUC) was included as a covariate in the ANOVAs, and we report the corrected statistics. Additionally, moderating effects of sex were explored by adding sex as a between-subjects factor in the ANOVAs. E<sub>max</sub> values were obtained directly from the observed data, and AUC and AUEC curves were calculated using the linear-log trapezoidal method in Phoenix WinNonlin 6.4 (Certara, Princeton, NJ).</p></sec></sec><sec id="Sec12"><title>Results</title><p id="Par19">Effects of the SNPs on the maximum response (E<sub>max</sub>) to MDMA are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. Supplementary Table S<xref rid="MOESM1" ref-type="media">1</xref> shows the data without adjustment for MDMA plasma concentrations. Supplementary Table S<xref rid="MOESM2" ref-type="media">2</xref> shows effects of the SNPs on the overall response to MDMA (AUEC values).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Effects of the SLC6A2 SNPs rs168924, rs47958, rs1861647, rs2242446, and rs36029 on the maximum response to MDMA (mean&#x02009;&#x000b1;&#x02009;SD and statistics)</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>
<bold>SNP rs168924</bold>
</td><td>Number of genotypes</td><td>AA</td><td>AG</td><td>GG</td><td>F</td><td>
<italic>p</italic> value</td><td>
<italic>p</italic> value (Bonferroni corr.)</td></tr><tr><td>
<italic>N</italic> (%)</td><td/><td>95 (77)</td><td>26 (21)</td><td>3 (2)</td><td/><td/><td/></tr><tr><td>Female, <italic>N</italic> (%)</td><td/><td>52 (55)</td><td>12 (46)</td><td>0 (0)</td><td/><td/><td/></tr><tr><td>MDMA plasma concentration AUC (ng/ml)</td><td>N 95, 26, 3</td><td>956&#x02009;&#x000b1;&#x02009;201</td><td>957&#x02009;&#x000b1;&#x02009;226</td><td>784&#x02009;&#x000b1;&#x02009;126</td><td>1.03</td><td>NS</td><td>NS</td></tr><tr><td>Norepinephrine &#x00394;plasma concentration at 2&#x000a0;h (pg/ml)</td><td>N 68, 14, 2</td><td>0.5&#x02009;&#x000b1;&#x02009;0.6</td><td>0.8&#x02009;&#x000b1;&#x02009;0.7</td><td>0.5&#x02009;&#x000b1;&#x02009;1.0</td><td>0.73</td><td>NS</td><td>NS</td></tr><tr><td>Subjective stimulation, &#x00394;E<sub>max</sub> (%)</td><td>N 95, 26, 3</td><td>63&#x02009;&#x000b1;&#x02009;33</td><td>72&#x02009;&#x000b1;&#x02009;33</td><td>41&#x02009;&#x000b1;&#x02009;42</td><td>1.07</td><td>NS</td><td>NS</td></tr><tr><td>Mean arterial pressure, &#x00394;E<sub>max</sub>, (mmHg)</td><td>N 95, 26, 3</td><td>18&#x02009;&#x000b1;&#x02009;10</td><td>20&#x02009;&#x000b1;&#x02009;9</td><td>13&#x02009;&#x000b1;&#x02009;15</td><td>0.66</td><td>NS</td><td>NS</td></tr><tr><td>Heart rate, &#x00394;E<sub>max</sub> (bpm)</td><td>N 95, 26, 3</td><td>19&#x02009;&#x000b1;&#x02009;15</td><td>18&#x02009;&#x000b1;&#x02009;15</td><td>17&#x02009;&#x000b1;&#x02009;17</td><td>0.04</td><td>NS</td><td>NS</td></tr><tr><td>Rate pressure product, &#x00394;E<sub>max</sub> (mmHg/min)</td><td>N 95, 26, 3</td><td>4678&#x02009;&#x000b1;&#x02009;2976</td><td>4869&#x02009;&#x000b1;&#x02009;3093</td><td>3937&#x02009;&#x000b1;&#x02009;3316</td><td>0.05</td><td>NS</td><td>NS</td></tr><tr><td>Pupil size, &#x00394;E<sub>max</sub> (mm)</td><td>N 93, 25, 3</td><td>0.9&#x02009;&#x000b1;&#x02009;0.5</td><td>1.0&#x02009;&#x000b1;&#x02009;0.4</td><td>0.7&#x02009;&#x000b1;&#x02009;0.4</td><td>0.62</td><td>NS</td><td>NS</td></tr><tr><td>Pupil size after light, &#x00394;E<sub>max</sub> (mm)</td><td>N 93, 25, 3</td><td>2.0&#x02009;&#x000b1;&#x02009;0.7</td><td>2.1&#x02009;&#x000b1;&#x02009;0.6</td><td>1.5&#x02009;&#x000b1;&#x02009;0.6</td><td>1.04</td><td>NS</td><td>NS</td></tr><tr><td>
<bold>SNP rs47958</bold>
</td><td>Number of genotypes</td><td>AA</td><td>AC</td><td>CC</td><td>F</td><td>
<italic>p</italic> value</td><td>
<italic>p</italic> value (Bonferroni corr.)</td></tr><tr><td>
<italic>N</italic> (%)</td><td/><td>27 (22)</td><td>58 (47)</td><td>39 (31)</td><td/><td/><td/></tr><tr><td>Female, <italic>N</italic> (%)</td><td/><td>13 (48)</td><td>29 (50)</td><td>22 (56)</td><td/><td/><td/></tr><tr><td>MDMA plasma concentration AUC (ng/ml)</td><td>N 27, 58, 39</td><td>941&#x02009;&#x000b1;&#x02009;177</td><td>954&#x02009;&#x000b1;&#x02009;234</td><td>957&#x02009;&#x000b1;&#x02009;181</td><td>0.06</td><td>NS</td><td>NS</td></tr><tr><td>Norepinephrine &#x00394;plasma concentration at 2&#x000a0;h (pg/ml)</td><td>N 18, 41, 25</td><td>0.4&#x02009;&#x000b1;&#x02009;0.8</td><td>0.5&#x02009;&#x000b1;&#x02009;0.7</td><td>0.6&#x02009;&#x000b1;&#x02009;0.6</td><td>0.29</td><td>NS</td><td>NS</td></tr><tr><td>Subjective stimulation, &#x00394;E<sub>max</sub> (%)</td><td>N 27, 58, 39</td><td>62&#x02009;&#x000b1;&#x02009;34</td><td>64&#x02009;&#x000b1;&#x02009;34</td><td>67&#x02009;&#x000b1;&#x02009;32</td><td>0.13</td><td>NS</td><td>NS</td></tr><tr><td>Mean arterial pressure, &#x00394;E<sub>max</sub> (mmHg)</td><td>N 27, 58, 39</td><td>21&#x02009;&#x000b1;&#x02009;10</td><td>17&#x02009;&#x000b1;&#x02009;8</td><td>18&#x02009;&#x000b1;&#x02009;11</td><td>1.99</td><td>NS</td><td>NS</td></tr><tr><td>Heart rate, &#x00394;E<sub>max</sub> (bpm)</td><td>N 27, 58, 39</td><td>21&#x02009;&#x000b1;&#x02009;14</td><td>20&#x02009;&#x000b1;&#x02009;16</td><td>14&#x02009;&#x000b1;&#x02009;14</td><td>2.41</td><td>NS</td><td>NS</td></tr><tr><td>Rate pressure product, &#x00394;E<sub>max</sub> (mmHg/min)</td><td>N 27, 58, 39</td><td>5391&#x02009;&#x000b1;&#x02009;2654</td><td>4882&#x02009;&#x000b1;&#x02009;3127</td><td>3950&#x02009;&#x000b1;&#x02009;2898</td><td>2.36</td><td>NS</td><td>NS</td></tr><tr><td>Pupil size, &#x00394;E<sub>max</sub> (mm)</td><td>N 27, 57, 37</td><td>0.8&#x02009;&#x000b1;&#x02009;0.3</td><td>1.0&#x02009;&#x000b1;&#x02009;0.4</td><td>0.9&#x02009;&#x000b1;&#x02009;0.6</td><td>1.48</td><td>NS</td><td>NS</td></tr><tr><td>Pupil size after light, &#x00394;E<sub>max</sub> (mm)</td><td>N 27, 57, 37</td><td>1.9&#x02009;&#x000b1;&#x02009;0.5</td><td>2.1&#x02009;&#x000b1;&#x02009;0.6</td><td>1.9&#x02009;&#x000b1;&#x02009;1.0</td><td>0.72</td><td>NS</td><td>NS</td></tr><tr><td>
<bold>SNP rs1861647</bold>
</td><td>Number of genotypes</td><td>AA</td><td>AG</td><td>GG</td><td>F</td><td>
<italic>p</italic> value</td><td>
<italic>p</italic> value (Bonferroni corr.)</td></tr><tr><td>
<italic>N</italic> (%)</td><td/><td>12 (10)</td><td>55 (45)</td><td>56 (46)</td><td/><td/><td/></tr><tr><td>Female, <italic>N</italic> (%)</td><td/><td>6 (50)</td><td>28 (51)</td><td>29 (52)</td><td/><td/><td/></tr><tr><td>MDMA plasma concentration AUC (ng/ml)</td><td>N 12, 55, 56</td><td>917&#x02009;&#x000b1;&#x02009;172</td><td>943&#x02009;&#x000b1;&#x02009;213</td><td>966&#x02009;&#x000b1;&#x02009;205</td><td>0.36</td><td>NS</td><td>NS</td></tr><tr><td>Norepinephrine &#x00394;plasma concentration at 2&#x000a0;h (pg/ml)</td><td>N 6, 39, 38</td><td>0.3&#x02009;&#x000b1;&#x02009;0.6</td><td>0.6&#x02009;&#x000b1;&#x02009;0.6</td><td>0.6&#x02009;&#x000b1;&#x02009;0.8</td><td>0.52</td><td>NS</td><td>NS</td></tr><tr><td>Subjective stimulation, &#x00394;E<sub>max</sub> (%)</td><td>N 12, 55, 56</td><td>73&#x02009;&#x000b1;&#x02009;29</td><td>62&#x02009;&#x000b1;&#x02009;32</td><td>64&#x02009;&#x000b1;&#x02009;36</td><td>0.79</td><td>NS</td><td>NS</td></tr><tr><td>Mean arterial pressure, &#x00394;E<sub>max</sub> (mmHg)</td><td>N 12, 55, 56</td><td>17&#x02009;&#x000b1;&#x02009;11</td><td>17&#x02009;&#x000b1;&#x02009;9</td><td>19&#x02009;&#x000b1;&#x02009;10</td><td>0.42</td><td>NS</td><td>NS</td></tr><tr><td>Heart rate, &#x00394;E<sub>max</sub> (bpm)</td><td>N 12, 55, 56</td><td>13&#x02009;&#x000b1;&#x02009;11</td><td>15&#x02009;&#x000b1;&#x02009;14**</td><td>23&#x02009;&#x000b1;&#x02009;15</td><td>4.90</td><td>0.009</td><td>0.045</td></tr><tr><td>Rate pressure product, &#x00394;E<sub>max</sub> (mmHg/min)</td><td>N 12, 55, 56</td><td>4025&#x02009;&#x000b1;&#x02009;2235</td><td>4018&#x02009;&#x000b1;&#x02009;3099*</td><td>5527&#x02009;&#x000b1;&#x02009;2851</td><td>3.74</td><td>0.027</td><td>NS</td></tr><tr><td>Pupil size, &#x00394;E<sub>max</sub> (mm)</td><td>N 12, 53, 55</td><td>0.8&#x02009;&#x000b1;&#x02009;0.3</td><td>0.9&#x02009;&#x000b1;&#x02009;0.5</td><td>0.9&#x02009;&#x000b1;&#x02009;0.4</td><td>0.37</td><td>NS</td><td>NS</td></tr><tr><td>Pupil size after light, &#x00394;E<sub>max</sub> (mm)</td><td>N 12, 53, 55</td><td>2.1&#x02009;&#x000b1;&#x02009;0.6</td><td>1.9&#x02009;&#x000b1;&#x02009;0.8</td><td>2.1&#x02009;&#x000b1;&#x02009;0.6</td><td>0.94</td><td>NS</td><td>NS</td></tr><tr><td>
<bold>SNP rs2242446</bold>
</td><td>Number of genotypes</td><td>CC</td><td>CT</td><td>TT</td><td>F</td><td>
<italic>p</italic> value</td><td>
<italic>p</italic> value (Bonferroni corr.)</td></tr><tr><td>
<italic>N</italic> (%)</td><td/><td>15 (12)</td><td>50 (40)</td><td>59 (48)</td><td/><td/><td/></tr><tr><td>Female, <italic>N</italic> (%)</td><td/><td>6 (40)</td><td>26 (52)</td><td>32 (54)</td><td/><td/><td/></tr><tr><td>MDMA plasma concentration AUC (ng/ml)</td><td>N 15, 50, 59</td><td>956&#x02009;&#x000b1;&#x02009;174</td><td>942&#x02009;&#x000b1;&#x02009;217</td><td>960&#x02009;&#x000b1;&#x02009;205</td><td>0.09</td><td>NS</td><td>NS</td></tr><tr><td>Norepinephrine &#x00394;plasma concentration at 2&#x000a0;h (pg/ml)</td><td>N 10, 36, 38</td><td>0.3&#x02009;&#x000b1;&#x02009;0.8</td><td>0.6&#x02009;&#x000b1;&#x02009;0.7</td><td>0.6&#x02009;&#x000b1;&#x02009;0.6</td><td>0.55</td><td>NS</td><td>NS</td></tr><tr><td>Subjective stimulation, &#x00394;E<sub>max</sub> (%)</td><td>N 15, 50, 59</td><td>72&#x02009;&#x000b1;&#x02009;33</td><td>65&#x02009;&#x000b1;&#x02009;31</td><td>61&#x02009;&#x000b1;&#x02009;36</td><td>0.77</td><td>NS</td><td>NS</td></tr><tr><td>Mean arterial pressure, &#x00394;E<sub>max</sub> (mmHg)</td><td>N 15, 50, 59</td><td>24&#x02009;&#x000b1;&#x02009;11</td><td>17&#x02009;&#x000b1;&#x02009;8***</td><td>17&#x02009;&#x000b1;&#x02009;10***</td><td>3.61</td><td>0.030</td><td>NS</td></tr><tr><td>Heart rate, &#x00394;E<sub>max</sub> (bpm)</td><td>N 15, 50, 59</td><td>26&#x02009;&#x000b1;&#x02009;18</td><td>21&#x02009;&#x000b1;&#x02009;16</td><td>14&#x02009;&#x000b1;&#x02009;12***</td><td>5.08</td><td>0.008</td><td>0.038</td></tr><tr><td>Rate pressure product, &#x00394;E<sub>max</sub> (mmHg/min)</td><td>N 15, 50, 59</td><td>6205&#x02009;&#x000b1;&#x02009;2997</td><td>5042&#x02009;&#x000b1;&#x02009;3191</td><td>4027&#x02009;&#x000b1;&#x02009;2642***</td><td>4.35</td><td>0.015</td><td>NS</td></tr><tr><td>Pupil size, &#x00394;E<sub>max</sub> (mm)</td><td>N 15, 48, 58</td><td>0.7&#x02009;&#x000b1;&#x02009;0.2</td><td>0.9&#x02009;&#x000b1;&#x02009;0.4</td><td>0.9&#x02009;&#x000b1;&#x02009;0.5</td><td>1.81</td><td>NS</td><td>NS</td></tr><tr><td>Pupil size after light, &#x00394;E<sub>max</sub> (mm)</td><td>N 15, 48, 58</td><td>1.9&#x02009;&#x000b1;&#x02009;0.5</td><td>1.9&#x02009;&#x000b1;&#x02009;0.5</td><td>2.1&#x02009;&#x000b1;&#x02009;0.9</td><td>0.97</td><td>NS</td><td>NS</td></tr><tr><td>
<bold>SNP rs36029</bold>
</td><td>Number of genotypes</td><td>AA</td><td>AG</td><td>GG</td><td>F</td><td>
<italic>p</italic> value</td><td>
<italic>p</italic> value (Bonferroni corr.)</td></tr><tr><td>
<italic>N</italic> (%)</td><td/><td>46 (37)</td><td>56 (45)</td><td>22 (18)</td><td/><td/><td/></tr><tr><td>Female, <italic>N</italic> (%)</td><td/><td>19 (41)</td><td>32 (57)</td><td>13 (59)</td><td/><td/><td/></tr><tr><td>MDMA plasma concentration AUC (ng/ml)</td><td>N 46, 56, 22</td><td>911&#x02009;&#x000b1;&#x02009;180</td><td>972&#x02009;&#x000b1;&#x02009;212</td><td>989&#x02009;&#x000b1;&#x02009;230</td><td>1.58</td><td>NS</td><td>NS</td></tr><tr><td>Norepinephrine &#x00394;plasma concentration at 2&#x000a0;h (pg/ml)</td><td>N 33, 37, 14</td><td>0.7&#x02009;&#x000b1;&#x02009;0.7</td><td>0.4&#x02009;&#x000b1;&#x02009;0.7</td><td>0.5&#x02009;&#x000b1;&#x02009;0.5</td><td>2.57</td><td>NS</td><td>NS</td></tr><tr><td>Subjective stimulation, &#x00394;E<sub>max</sub> (%)</td><td>N 46, 56, 22</td><td>65&#x02009;&#x000b1;&#x02009;33</td><td>64&#x02009;&#x000b1;&#x02009;33</td><td>62&#x02009;&#x000b1;&#x02009;38</td><td>0.50</td><td>NS</td><td>NS</td></tr><tr><td>Mean arterial pressure, &#x00394;E<sub>max</sub> (mmHg)</td><td>N 46, 56, 22</td><td>20&#x02009;&#x000b1;&#x02009;10</td><td>16&#x02009;&#x000b1;&#x02009;10</td><td>17&#x02009;&#x000b1;&#x02009;9</td><td>4.82</td><td>0.010</td><td>0.049</td></tr><tr><td>Heart rate, &#x00394;E<sub>max</sub> (bpm)</td><td>N 46, 56, 22</td><td>21&#x02009;&#x000b1;&#x02009;16</td><td>17&#x02009;&#x000b1;&#x02009;15</td><td>16&#x02009;&#x000b1;&#x02009;14</td><td>2.12</td><td>NS</td><td>NS</td></tr><tr><td>Rate pressure product, &#x00394;E<sub>max</sub> (mmHg/min)</td><td>N 46, 56, 22</td><td>5419&#x02009;&#x000b1;&#x02009;2974</td><td>4317&#x02009;&#x000b1;&#x02009;3067</td><td>4169&#x02009;&#x000b1;&#x02009;2608</td><td>3.47</td><td>0.034</td><td>NS</td></tr><tr><td>Pupil size, &#x00394;E<sub>max</sub> (mm)</td><td>N 46, 54, 21</td><td>0.9&#x02009;&#x000b1;&#x02009;0.3</td><td>0.9&#x02009;&#x000b1;&#x02009;0.4</td><td>0.8&#x02009;&#x000b1;&#x02009;0.6</td><td>0.62</td><td>NS</td><td>NS</td></tr><tr><td>Pupil size after light, &#x00394;E<sub>max</sub> (mm)</td><td>N 46, 54, 21</td><td>1.9&#x02009;&#x000b1;&#x02009;0.5</td><td>2.1&#x02009;&#x000b1;&#x02009;0.7</td><td>1.9&#x02009;&#x000b1;&#x02009;1.0</td><td>1.25</td><td>NS</td><td>NS</td></tr></tbody></table><table-wrap-foot><p>F and <italic>p</italic> values are from ANCOVAs (except for the MDMA concentrations) with MDMA AUC as covariate to account for differences in MDMA concentrations</p><p>
<italic>N</italic> number of subjects, <italic>SNP</italic> single nucleotide polymorphism, <italic>E</italic>
<sub><italic>max</italic></sub> peak effect, <italic>AUC</italic> area under the concentration-time curve from 0 to 6&#x000a0;h, <italic>NS</italic> not significant, <italic>&#x00394;</italic> values are change scores from placebo (mdma-placebo)</p><p>*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 compared to rs1861647 GG; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to rs2242446 CC</p></table-wrap-foot></table-wrap>
</p><sec id="Sec13"><title>Genotyping</title><p id="Par20">The distribution of the alleles and genotypes did not differ from the distributions that were reported elsewhere in Caucasian cohorts (Ensembl database release 88, Mar 2017). The minor allele frequencies for rs168924, rs47958, rs1861647, rs2242446, rs36029, and rs1048101 were G (29 [13%]), A (112 [45%]), A (79 [32%]), C (80 [33%]), G (100 [40%]), and G (107 [43%]), respectively. The tested genetic variants were consistent with the Hardy-Weinberg equilibrium (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05) with the exception of rs1048101 (<italic>p</italic>&#x02009;=&#x02009;0.01).</p></sec><sec id="Sec14"><title>Plasma concentrations of MDMA and norepinephrine</title><p id="Par21">Plasma concentrations of MDMA and norepinephrine did not differ between the different genotype groups (Table <xref rid="Tab1" ref-type="table">1</xref> and Supplementary Table S<xref rid="MOESM1" ref-type="media">1</xref>).</p></sec><sec id="Sec15"><title>Subjective effects</title><p id="Par22">None of the examined polymorphisms influenced subjective stimulation that was induced by MDMA (Table <xref rid="Tab1" ref-type="table">1</xref>, Supplementary Tables S<xref rid="MOESM1" ref-type="media">1</xref> and S<xref rid="MOESM2" ref-type="media">2</xref>).</p></sec><sec id="Sec16"><title>Pupillary effects</title><p id="Par23">None of the examined polymorphisms influenced the MDMA-induced change in pupillary size before and after light stimulus (Table <xref rid="Tab1" ref-type="table">1</xref> and Supplementary Tables S<xref rid="MOESM1" ref-type="media">1</xref> and S<xref rid="MOESM2" ref-type="media">2</xref>).</p></sec><sec id="Sec17"><title>Cardiovascular effects</title><p id="Par24">The effects of the polymorphisms on elevations of MAP, heart rate, and RPP in response to MDMA (adjusted for differences in plasma MDMA concentrations) are shown in Table <xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The rs1861647 SNP located in <italic>SLC6A2</italic> significantly altered the elevations of heart rate and RPP after MDMA administration. The effect on the heart rate remained significant after Bonferroni correction for multiple testing (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Subjects with the GG genotype had significantly higher elevations of heart rate and RPP after MDMA administration than subjects with the AG genotype. When we combined the AA and AG genotype groups, subjects with the GG genotype presented higher elevations of heart rate and RPP than carriers of the minor A allele (<italic>F</italic>
<sub>1,120</sub>&#x02009;=&#x02009;9.79, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 and <italic>F</italic>
<sub>1,120</sub>&#x02009;=&#x02009;7.53, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, respectively). These effects remained significant after Bonferroni correction for multiple testing (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.02 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.04, respectively).<fig id="Fig1"><label>Fig. 1</label><caption><p>Effects of common genetic variants of the <italic>SLC6A2</italic> gene (rs168924, rs47958, rs1861647, rs2242446, and rs36029) on cardiovascular stimulation after MDMA administration in 124 healthy subjects. Homozygous carriers of <italic>SLC6A2</italic> rs1861647 G allele presented higher elevations of heart rate and rate-pressure product after MDMA than subjects with one G allele. Subjects with the CC genotype of the <italic>SLC6A2</italic> rs2242446 SNP presented higher elevations of heart rate, mean arterial pressure, and rate-pressure product after MDMA administration compared with the TT genotype group. The <italic>SLC6A2</italic> rs168924 and rs47958 SNPs did not significantly alter the response to MDMA. The corresponding maximal effects and statistics are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. The data are expressed as mean&#x02009;&#x000b1;&#x02009;SEM. MDMA or placebo was administered at time&#x02009;=&#x02009;0</p></caption><graphic xlink:href="228_2017_2392_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par25">The rs2242446 SNP significantly moderated the elevation of RPP after MDMA administration, which was attributable to significant moderating effects on MDMA-induced changes in MAP and heart rate. The CC genotype presented elevations of heart rate, MAP, and RPP after MDMA administration compared with the TT genotype. When we combined the rs2242446 CT and CC genotype groups, subjects with the TT genotype presented lower elevations of heart rate and RPP than carriers of the C allele (<italic>F</italic>
<sub>1,121</sub>&#x02009;=&#x02009;7.81, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 and <italic>F</italic>
<sub>1,121</sub>&#x02009;=&#x02009;5.64, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively). The difference between the genotype groups and the combined groups (TT and CT/CC) in the effects of MDMA on heart rate remained significant after Bonferroni correction for multiple testing (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.04 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.04, respectively).</p><p id="Par26">Significant main effects of the rs36029 SNP on MDMA-induced elevations of MAP and RPP were found. When we combined the rs36029 AG and GG genotype groups, subjects with the AA genotype presented higher elevations of MAP, heart rate, and RPP than carriers of the G allele (<italic>F</italic>
<sub>1,121</sub>&#x02009;=&#x02009;9.870, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; <italic>F</italic>
<sub>1,121</sub>&#x02009;=&#x02009;4.24, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; and <italic>F</italic>
<sub>1,121</sub>&#x02009;=&#x02009;6.91, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, respectively). The difference in the effects of MDMA on MAP between the genotype groups and difference in the effects of MDMA on MAP and RPP between the combined groups (AA and AG/GG) remained significant after Bonferroni correction for multiple testing (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.02, and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, respectively).</p><p id="Par27">The effects of the rs1861647, rs2242446, and rs36029 SNPs on the peak response to MDMA were similar when the analyses were performed without using MDMA plasma concentrations as covariate in the ANOVAs (Supplementary Table S<xref rid="MOESM1" ref-type="media">1</xref>). However, none of the SNPs altered the overall cardiovascular response to MDMA as expressed by the AUEC values (Supplementary Table S<xref rid="MOESM2" ref-type="media">2</xref>) with the exception of the effect of the rs36029 SNP on the MAP.</p><p id="Par28">The rs168924 and rs47958 SNPs did not alter the effects of MDMA. When we applied Bonferroni correction for multiple testing (for five SNPs), none of the statistical findings remained significant in the additive genotype group models (Table <xref rid="Tab1" ref-type="table">1</xref>) with the exception of the effect of the rs2242446 SNP on heart rate, and sex did not alter the influence of the SNPs on the response to MDMA (Supplementary Table S<xref rid="MOESM3" ref-type="media">3</xref>).</p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par29">The present study investigated the effect of interindividual differences in the <italic>SLC6A2</italic> gene on the cardiovascular and subjective stimulant response to MDMA. None of the investigated SNPs moderated the subjective stimulant effects of MDMA. Three SNPs of the <italic>SLC6A2</italic> gene (rs1861647, rs2242446, and rs36029) influenced the cardiovascular response to MDMA. However, the effect sizes for these genetic variants were rather small and not very robust. In fact, Bonferroni correction of the data for the five SNPs resulted in the loss of most statistical significance. Thus, although the NET has been implicated in the stimulant-type response to MDMA [<xref ref-type="bibr" rid="CR7">7</xref>], the genetic variants of the NET gene (<italic>SLC6A2</italic>) that were evaluated herein only minimally influenced the response to MDMA.</p><p id="Par30">To our knowledge, the present study was the first to explore the role of SNPs of the <italic>SLC6A2</italic> gene in the response to MDMA. Thus, no comparisons can be made with other studies that tested MDMA. In a previous study, C-allele carriers of the <italic>SLC6A2</italic> rs2242446 SNP presented higher blood pressure after physical exercise [<xref ref-type="bibr" rid="CR28">28</xref>], which is consistent with the greater blood pressure response in the present study following the administration of a pharmacological stimulant. Additionally, plasma NE concentrations after exercise differed between different rs2242446 genotypes [<xref ref-type="bibr" rid="CR28">28</xref>]. In the present study, however, no differences in NE levels after MDMA administration were found between genotype groups. The effects of the <italic>SLC6A2</italic> rs1861647 and rs47958 SNPs on the response to <sc>d</sc>-amphetamine have previously been reported [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Initial studies showed that subjects with the AA genotype of rs1861647 had higher vigor scores after <sc>d</sc>-amphetamine administration [<xref ref-type="bibr" rid="CR26">26</xref>]. Additionally, subjects with the CC genotype of rs47958 had higher positive mood scores [<xref ref-type="bibr" rid="CR27">27</xref>]. However, a subsequent larger replication study found no influence of the different rs1861647 and rs47958 genotypes on the response to <sc>d</sc>-amphetamine [<xref ref-type="bibr" rid="CR39">39</xref>] as similarly documented in the present study for the subjective response to MDMA. However, the effects of <italic>SLC6A2</italic> SNPs on the cardiovascular response to <sc>d</sc>-amphetamine or MDMA have not been studied previously; therefore, the role of the rs1861647 SNP in the cardiovascular stimulant effects of MDMA that was identified in the present study needs further investigation.</p><p id="Par31">Additionally, none of the NET genotypes moderated the MDMA-induced increase in pupil size [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par32">The present study has several limitations. First, the sample size was relatively small when considering the mostly small effect sizes for the influence of genetic variants on the MDMA response. Additionally, significant findings in the additive genotype models were mostly lost after Bonferroni correction. Confirmation in studies with larger samples is needed. However, we unlikely missed very large effect sizes for the influence of these genetic variants or possible haplotypes. Second, the study was conducted in mostly young and healthy volunteers. Therefore, the findings cannot necessarily be generalized to people with hypertension or other cardiovascular risk factors. Third, SNPs of the genes of other targets of MDMA, such as the 5-HT transporter [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], may also be involved but were not tested in the present study. However, we considered the moderating effects of known genetic variants that influence the metabolism of MDMA [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] by accounting for interindividual differences in plasma MDMA concentrations.</p><p id="Par33">In conclusion, the present study investigated the influence of genetic polymorphisms of the <italic>SLC6A2</italic> gene on the response to MDMA. Three SNPs of the <italic>SLC6A2</italic> gene (rs2242446, rs1861647, and rs36029) weakly altered the cardiovascular effects of MDMA in healthy subjects. It can be assumed that these genetic polymorphisms may play a minor role in adverse cardiovascular events when MDMA is used recreationally or therapeutically.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec19"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="228_2017_2392_MOESM1_ESM.xlsx"><label>ESM 1</label><caption><p>(XLSX 19&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="228_2017_2392_MOESM2_ESM.xlsx"><label>ESM 2</label><caption><p>(XLSX 16&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="228_2017_2392_MOESM3_ESM.xlsx"><label>ESM 3</label><caption><p>(XLSX 17&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1007/s00228-017-2392-2) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors acknowledge the assistance of C. M. Hysek, A. Rickli, Y. Schmid, and P. C. Dolder in conducting the clinical studies; K. Prestin for the assistance with the genotyping; and M. Arends for the text editing.</p></ack><notes notes-type="author-contribution"><title>Author contribution</title><p>PV analyzed data and wrote the manuscript. HM analyzed the data. MEL conceived the study, obtained funding, analyzed the data, and wrote the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding information</title><p>This study was supported by the Swiss National Science Foundation (grant no. 320030_149493 and 320030_170249).</p></notes><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p id="Par34">The authors declare that they have no conflicts of interest.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>MDMA enhances emotional empathy and prosocial behavior</article-title><source>Soc Cogn Affect Neurosci</source><year>2014</year><volume>9</volume><issue>11</issue><fpage>1645</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1093/scan/nst161</pub-id><pub-id pub-id-type="pmid">24097374</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardle</surname><given-names>MC</given-names></name><name><surname>Kirkpatrick</surname><given-names>MG</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>&#x02018;Ecstasy&#x02019; as a social drug: MDMA preferentially affects responses to emotional stimuli with social content</article-title><source>Soc Cogn Affect Neurosci</source><year>2014</year><volume>9</volume><issue>8</issue><fpage>1076</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1093/scan/nsu035</pub-id><pub-id pub-id-type="pmid">24682132</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oehen</surname><given-names>P</given-names></name><name><surname>Traber</surname><given-names>R</given-names></name><name><surname>Widmer</surname><given-names>V</given-names></name><name><surname>Schnyder</surname><given-names>U</given-names></name></person-group><article-title>A randomized, controlled pilot study of MDMA (&#x000b1;3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD)</article-title><source>J Psychopharmacol</source><year>2013</year><volume>27</volume><issue>1</issue><fpage>40</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1177/0269881112464827</pub-id><pub-id pub-id-type="pmid">23118021</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mithoefer</surname><given-names>MC</given-names></name><name><surname>Wagner</surname><given-names>MT</given-names></name><name><surname>Mithoefer</surname><given-names>AT</given-names></name><name><surname>Jerome</surname><given-names>I</given-names></name><name><surname>Doblin</surname><given-names>R</given-names></name></person-group><article-title>The safety and efficacy of &#x000b1;3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study</article-title><source>J Psychopharmacol</source><year>2010</year><volume>25</volume><issue>4</issue><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1177/0269881110378371</pub-id><pub-id pub-id-type="pmid">20643699</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaekers</surname><given-names>JG</given-names></name><name><surname>Kuypers</surname><given-names>KP</given-names></name><name><surname>Samyn</surname><given-names>N</given-names></name></person-group><article-title>Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal</article-title><source>Addiction</source><year>2006</year><volume>101</volume><issue>11</issue><fpage>1614</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.2006.01566.x</pub-id><pub-id pub-id-type="pmid">17034441</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizeli</surname><given-names>P</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Safety pharmacology of acute MDMA administration in healthy subjects</article-title><source>J Psychopharmacol</source><year>2017</year><volume>31</volume><issue>5</issue><fpage>576</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1177/0269881117691569</pub-id><pub-id pub-id-type="pmid">28443695</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Ineichen</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Brenneisen</surname><given-names>R</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (&#x0201c;ecstasy&#x0201d;) in humans</article-title><source>Clin Pharmacol Ther</source><year>2011</year><volume>90</volume><issue>2</issue><fpage>246</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/clpt.2011.78</pub-id><pub-id pub-id-type="pmid">21677639</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Gamma</surname><given-names>A</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Gender differences in the subjective effects of MDMA</article-title><source>Psychopharmacology</source><year>2001</year><volume>154</volume><issue>2</issue><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1007/s002130000648</pub-id><pub-id pub-id-type="pmid">11314678</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizeli</surname><given-names>P</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Prestin</surname><given-names>K</given-names></name><name><surname>Meyer zu Schwabedissen</surname><given-names>HE</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects</article-title><source>Eur Neuropsychopharmacol</source><year>2017</year><volume>27</volume><issue>3</issue><fpage>232</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2017.01.008</pub-id><pub-id pub-id-type="pmid">28117133</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Vizeli</surname><given-names>P</given-names></name><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Prestin</surname><given-names>K</given-names></name><name><surname>Meyer zu Schwabedissen</surname><given-names>HE</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of MDMA in a controlled study in healthy subjects</article-title><source>Pharmacogenet Genomics</source><year>2016</year><volume>26</volume><issue>8</issue><fpage>397</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1097/FPC.0000000000000231</pub-id><pub-id pub-id-type="pmid">27253829</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bershad</surname><given-names>AK</given-names></name><name><surname>Weafer</surname><given-names>JJ</given-names></name><name><surname>Kirkpatrick</surname><given-names>MG</given-names></name><name><surname>Wardle</surname><given-names>MC</given-names></name><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Oxytocin receptor gene variation predicts subjective responses to MDMA</article-title><source>Soc Neurosci</source><year>2016</year><volume>11</volume><issue>6</issue><fpage>592</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1080/17470919.2016.1143026</pub-id><pub-id pub-id-type="pmid">26787430</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre</surname><given-names>R</given-names></name><name><surname>Yubero-Lahoz</surname><given-names>S</given-names></name><name><surname>Pardo-Lozano</surname><given-names>R</given-names></name><name><surname>Farre</surname><given-names>M</given-names></name></person-group><article-title>MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relvant?</article-title><source>Front Genet</source><year>2012</year><volume>3</volume><fpage>235</fpage><pub-id pub-id-type="pmid">23162568</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Nicola</surname><given-names>V</given-names></name><name><surname>Vischer</surname><given-names>N</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Kr&#x000e4;henb&#x000fc;hl</surname><given-names>S</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Duloxetine inhibits effects of MDMA (&#x0201c;ecstasy&#x0201d;) in vitro and in humans in a randomized placebo-controlled laboratory study</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>5</issue><fpage>e36476</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0036476</pub-id><pub-id pub-id-type="pmid">22574166</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothman</surname><given-names>RB</given-names></name><name><surname>Baumann</surname><given-names>MH</given-names></name><name><surname>Dersch</surname><given-names>CM</given-names></name><name><surname>Romero</surname><given-names>DV</given-names></name><name><surname>Rice</surname><given-names>KC</given-names></name><name><surname>Carroll</surname><given-names>FI</given-names></name><name><surname>Partilla</surname><given-names>JS</given-names></name></person-group><article-title>Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin</article-title><source>Synapse</source><year>2001</year><volume>39</volume><issue>1</issue><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/1098-2396(20010101)39:1&#x0003c;32::AID-SYN5&#x0003e;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">11071707</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudnick</surname><given-names>G</given-names></name><name><surname>Wall</surname><given-names>SC</given-names></name></person-group><article-title>The molecular mechanism of &#x0201c;ecstasy&#x0201d; [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release</article-title><source>Proc Natl Acad Sci U S A</source><year>1992</year><volume>89</volume><issue>5</issue><fpage>1817</fpage><lpage>1821</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.5.1817</pub-id><pub-id pub-id-type="pmid">1347426</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmler</surname><given-names>L</given-names></name><name><surname>Buser</surname><given-names>T</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Schramm</surname><given-names>Y</given-names></name><name><surname>Dieu</surname><given-names>LH</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Chaboz</surname><given-names>S</given-names></name><name><surname>Hoener</surname><given-names>M</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacological characterization of designer cathinones in vitro</article-title><source>Br J Pharmacol</source><year>2013</year><volume>168</volume><issue>2</issue><fpage>458</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02145.x</pub-id><pub-id pub-id-type="pmid">22897747</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verrico</surname><given-names>CD</given-names></name><name><surname>Miller</surname><given-names>GM</given-names></name><name><surname>Madras</surname><given-names>BK</given-names></name></person-group><article-title>MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment</article-title><source>Psychopharmacology</source><year>2007</year><volume>189</volume><issue>4</issue><fpage>489</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1007/s00213-005-0174-5</pub-id><pub-id pub-id-type="pmid">16220332</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (&#x02018;ecstasy&#x02019;) in healthy volunteers</article-title><source>J Psychopharmacol</source><year>2000</year><volume>14</volume><issue>3</issue><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1177/026988110001400313</pub-id><pub-id pub-id-type="pmid">11106307</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Fink</surname><given-names>AE</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Alpha-adrenergic receptors contribute to the acute effects of MDMA in humans</article-title><source>J Clin Psychopharmacol</source><year>2013</year><volume>33</volume><issue>5</issue><fpage>658</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e3182979d32</pub-id><pub-id pub-id-type="pmid">23857311</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofuoglu</surname><given-names>M</given-names></name><name><surname>Poling</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>K</given-names></name><name><surname>Kosten</surname><given-names>T</given-names></name></person-group><article-title>Atomoxetine attenuates dextroamphetamine effects in humans</article-title><source>Am J Drug Alcohol Abuse</source><year>2009</year><volume>35</volume><issue>6</issue><fpage>412</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.3109/00952990903383961</pub-id><pub-id pub-id-type="pmid">20014909</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex</article-title><source>Psychopharmacology</source><year>2012</year><volume>224</volume><issue>3</issue><fpage>363</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1007/s00213-012-2761-6</pub-id><pub-id pub-id-type="pmid">22700038</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>TF</given-names></name></person-group><article-title>A perhaps unexpected role of norepinephrine in actions of MDMA</article-title><source>Clin Pharmacol Ther</source><year>2011</year><volume>90</volume><issue>2</issue><fpage>215</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/clpt.2011.125</pub-id><pub-id pub-id-type="pmid">21772299</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoops</surname><given-names>WW</given-names></name><name><surname>Blackburn</surname><given-names>JW</given-names></name><name><surname>Hudson</surname><given-names>DA</given-names></name><name><surname>Hays</surname><given-names>LR</given-names></name><name><surname>Rush</surname><given-names>CR</given-names></name></person-group><article-title>Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance</article-title><source>Drug Alcohol Depend</source><year>2008</year><volume>92</volume><issue>1-3</issue><fpage>282</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2007.07.005</pub-id><pub-id pub-id-type="pmid">17719727</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Iwanaga</surname><given-names>Y</given-names></name><name><surname>Mannami</surname><given-names>T</given-names></name><name><surname>Kokubo</surname><given-names>Y</given-names></name><name><surname>Tomoike</surname><given-names>H</given-names></name><name><surname>Komamura</surname><given-names>K</given-names></name><name><surname>Shioji</surname><given-names>K</given-names></name><name><surname>Yasui</surname><given-names>N</given-names></name><name><surname>Tago</surname><given-names>N</given-names></name><name><surname>Iwai</surname><given-names>N</given-names></name></person-group><article-title>Epidemiological evidence of an association between SLC6A2 gene polymorphism and hypertension</article-title><source>Hypertens Res</source><year>2003</year><volume>26</volume><issue>9</issue><fpage>685</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1291/hypres.26.685</pub-id><pub-id pub-id-type="pmid">14620922</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zolk</surname><given-names>O</given-names></name><name><surname>Ott</surname><given-names>C</given-names></name><name><surname>Fromm</surname><given-names>MF</given-names></name><name><surname>Schmieder</surname><given-names>RE</given-names></name></person-group><article-title>Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians</article-title><source>J Clin Hypertens (Greenwich)</source><year>2012</year><volume>14</volume><issue>5</issue><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7176.2012.00618.x</pub-id><pub-id pub-id-type="pmid">22533655</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dlugos</surname><given-names>AM</given-names></name><name><surname>Hamidovic</surname><given-names>A</given-names></name><name><surname>Palmer</surname><given-names>AA</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Further evidence of association between amphetamine response and SLC6A2 gene variants</article-title><source>Psychopharmacology</source><year>2009</year><volume>206</volume><issue>3</issue><fpage>501</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1007/s00213-009-1628-y</pub-id><pub-id pub-id-type="pmid">19727679</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dlugos</surname><given-names>A</given-names></name><name><surname>Freitag</surname><given-names>C</given-names></name><name><surname>Hohoff</surname><given-names>C</given-names></name><name><surname>McDonald</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>EH</given-names></name><name><surname>Deckert</surname><given-names>J</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Norepinephrine transporter gene variation modulates acute response to D-amphetamine</article-title><source>Biol Psychiatry</source><year>2007</year><volume>61</volume><issue>11</issue><fpage>1296</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2006.09.031</pub-id><pub-id pub-id-type="pmid">17239355</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohli</surname><given-names>U</given-names></name><name><surname>Hahn</surname><given-names>MK</given-names></name><name><surname>English</surname><given-names>BA</given-names></name><name><surname>Sofowora</surname><given-names>GG</given-names></name><name><surname>Muszkat</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>Stein</surname><given-names>CM</given-names></name><name><surname>Kurnik</surname><given-names>D</given-names></name></person-group><article-title>Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans</article-title><source>Pharmacogenet Genomics</source><year>2011</year><volume>21</volume><issue>4</issue><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">21412203</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>MK</given-names></name><name><surname>Blackford</surname><given-names>JU</given-names></name><name><surname>Haman</surname><given-names>K</given-names></name><name><surname>Mazei-Robison</surname><given-names>M</given-names></name><name><surname>English</surname><given-names>BA</given-names></name><name><surname>Prasad</surname><given-names>HC</given-names></name><name><surname>Steele</surname><given-names>A</given-names></name><name><surname>Hazelwood</surname><given-names>L</given-names></name><name><surname>Fentress</surname><given-names>HM</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>Sanders-Bush</surname><given-names>E</given-names></name><name><surname>Shelton</surname><given-names>R</given-names></name></person-group><article-title>Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression</article-title><source>Genes Brain Behav</source><year>2008</year><volume>7</volume><issue>4</issue><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1111/j.1601-183X.2007.00384.x</pub-id><pub-id pub-id-type="pmid">18081710</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Higuchi</surname><given-names>H</given-names></name><name><surname>Kamata</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Naito</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Nemeroff</surname><given-names>CB</given-names></name></person-group><article-title>Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms</article-title><source>Am J Psychiatry</source><year>2004</year><volume>161</volume><issue>9</issue><fpage>1575</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.161.9.1575</pub-id><pub-id pub-id-type="pmid">15337646</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>TK</given-names></name><name><surname>Dempster</surname><given-names>E</given-names></name><name><surname>Docherty</surname><given-names>SJ</given-names></name><name><surname>Desrivieres</surname><given-names>S</given-names></name><name><surname>Lourdsamy</surname><given-names>A</given-names></name><name><surname>Wodarz</surname><given-names>N</given-names></name><name><surname>Ridinger</surname><given-names>M</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Rietschel</surname><given-names>M</given-names></name><name><surname>Schumann</surname><given-names>G</given-names></name></person-group><article-title>Multiple polymorphisms in genes of the adrenergic stress system confer vulnerability to alcohol abuse</article-title><source>Addict Biol</source><year>2012</year><volume>17</volume><issue>1</issue><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1111/j.1369-1600.2010.00263.x</pub-id><pub-id pub-id-type="pmid">21070505</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Brugger</surname><given-names>R</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Bruggisser</surname><given-names>M</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Effects of the alpha2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>340</volume><issue>2</issue><fpage>286</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1124/jpet.111.188425</pub-id><pub-id pub-id-type="pmid">22034656</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Rickli</surname><given-names>A</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans</article-title><source>Br J Pharmacol</source><year>2012</year><volume>166</volume><issue>8</issue><fpage>2277</fpage><lpage>2288</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.01936.x</pub-id><pub-id pub-id-type="pmid">22404145</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Schillinger</surname><given-names>N</given-names></name><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination</article-title><source>Int J Neuropsychopharmacol</source><year>2014</year><volume>17</volume><issue>03</issue><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1017/S1461145713001132</pub-id><pub-id pub-id-type="pmid">24103254</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Rickli</surname><given-names>A</given-names></name><name><surname>Schaffner</surname><given-names>A</given-names></name><name><surname>Duthaler</surname><given-names>U</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects</article-title><source>J Pharmacol Exp Ther</source><year>2015</year><volume>353</volume><issue>1</issue><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1124/jpet.114.222356</pub-id><pub-id pub-id-type="pmid">25655950</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Dolder PC, Muller F, Schmid Y, Borgwardt SJ, Liechti ME (2017) Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology (in press). 10.1007/s00213-017-4650-5</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunt</surname><given-names>TM</given-names></name><name><surname>Koeter</surname><given-names>MW</given-names></name><name><surname>Niesink</surname><given-names>RJ</given-names></name><name><surname>van den Brink</surname><given-names>W</given-names></name></person-group><article-title>Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users</article-title><source>Psychopharmacology</source><year>2012</year><volume>220</volume><issue>4</issue><fpage>751</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2529-4</pub-id><pub-id pub-id-type="pmid">21993879</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunand</surname><given-names>M</given-names></name><name><surname>Gubian</surname><given-names>D</given-names></name><name><surname>Stauffer</surname><given-names>M</given-names></name><name><surname>Abid</surname><given-names>KA</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name></person-group><article-title>High throughput and sensitive quantitation of plasma catecholamines by ultraperformance liquid chromatography-tandem mass spectrometry using a solid phase microwell extraction plate</article-title><source>Anal Chem</source><year>2013</year><volume>85</volume><issue>7</issue><fpage>3539</fpage><lpage>3544</lpage><pub-id pub-id-type="doi">10.1021/ac4004584</pub-id><pub-id pub-id-type="pmid">23432705</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>AB</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name><name><surname>Palmer</surname><given-names>AA</given-names></name></person-group><article-title>Candidate gene studies of a promising intermediate phenotype: failure to replicate</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><issue>5</issue><fpage>802</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1038/npp.2012.245</pub-id><pub-id pub-id-type="pmid">23303064</pub-id></element-citation></ref></ref-list></back></article>